MRZM
MARIZYME INC
Latest price
As of — · Market data by Massive
Market cap
—
Volume
—
Previous close
—
Day range
—
Listed
—
Coverage
6 articles
Price performance
Recent trading
Newsroom
Latest MRZM coverage
Marizyme CEO Delivers Business Update
[ad_1] JUPITER, FL – (NewMediaWire) – October 23, 2023 – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel: “I am very pleased to bring you an update on the Company’s FDA Clearance for
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft
[ad_1] DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries JUPITER, FL – (NewMediaWire) – October 06, 2023 – Marizyme, Inc. (OTCQB:MRZM) (“Marizyme” or the “Company”), a global medical technology company focused on the developmen
Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing
[ad_1] Jupiter, FL – (NewMediaWire) – December 23, 2021 – Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the closing of its acquisition of My Health Logic Inc., a subsidiary of Health Logic Interactive Inc. (TSXV:CHIP.H), along with a concurrent financing. My Health Logic’s “lab-on-
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
[ad_1] JUPITER, FL – (NewMediaWire) – December 03, 2021 – Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and diagnose diseases of unmet clinical need announced today that results of the GOAL Study (Vienna Heart Center Floridsdorf/PI Dr. Winkler Bernhard) were pres
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
[ad_1] Jupiter, FL – (NewMediaWire) – December 3, 2021 – Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to prevent, treat and diagnose diseases of unmet clinical need, announced today that it has received notice of allowance for foundational patent applications
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
[ad_1] JUPITER, Fla. – (NewMediaWire) – November 16, 2021 – Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme. In his role Mr. Barthel will look to advance the Company’s technology pipeline and stay committed to the